TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search results
In a sign that the government is ready to move beyond the pandemic toward developing the health sector, people must start footing their own bills for COVID-19 treatment and vaccination on Sept. 1, whether independently or through insurance.
Like Kim, many have turned to telemedicine in South Korea in recent weeks as access to in-person options has been hit after authorities said they would only provide care to COVID patients aged 60 and above amid record-high Omicron cases and prescribed home care for those with mild symptoms.
Phase-three clinical trials conducted by AstraZeneca suggest that a single dose of the antibody combination AZD7442 (commercially called Evusheld) is 83 percent effective at preventing severe COVID-19 in people over the age of 18 and could offer protection more than six months after administration.
The government recently kicked off a national campaign to encourage COVID-19 survivors to donate their convalescent plasma for patients, despite other countries having halted the treatment following undesired results.
Researchers in Costa Rica are due to begin trials of an inexpensive coronavirus treatment based on antibodies taken from horses injected with the SARS-Cov-2, the virus that causes COVID-19, according to scientists.
Dr Stephen Hahn, the commissioner of the US Food and Drug Administration, apologized Monday after misrepresenting a key statistic on how effective blood plasma is for treating COVID-19 when announcing an emergency approval measure.
AstraZeneca said on Tuesday it had begun testing an antibody-based treatment for the prevention and treatment of COVID-19, with the first participants dosed, adding to recent signs of progress on possible medical solutions to the disease.
The United States has issued an emergency authorization to use blood plasma from recovered COVID-19 patients as a treatment against the disease.Is it safe and effective? Has President Donald Trump's administration put political considerations ahead of the science? Here's what you need to know.
